CLiX unlock enterprise

Rapidly identify specific patient cohorts in a matter of hours with CLiX® unlock enterprise.

CLiX® unlock enterprise

Pharmaceutical organisations are utilising the power of CLiX unlock enterprise to drastically reduce the task of feasibility work and pre-screening, quickly locating specific cohorts within large patient populations. This, in turn, helps improve market access post-launch, especially in complex therapeutic areas, such as oncology and rare disease.

Why use CLiX unlock enterprise?


Rapidly interrogate data

Reduce the elapsed time and effort needed to analyse clinical data


Identify the critical signals

Pin-point the granular clinical signals to understand your market or drive clinical research requirements

Optimise resource efficiency

Minimise manual chart review, reallocate clinical resource


Key features & benefits

Key Feature:

Analyses clinical free text written by physicians during the delivery of care in documents such as discharge summaries, radiology reports.


Obtain very detailed insights into clinical data that cannot be gained from structured coded data.

Key Feature:

Designed to operate at a large scale and work with millions of clinical documents.


Save elapsed time and cost to gain population-level insights.

Key Feature:

Supports a patient-centric model.


Enables longitudinal analysis of detailed clinical signals and patterns.

What CLiX® unlock enterprise users say...

“Addressing healthcare ecosystem challenges to enable earlier detection and diagnosis of cancer is one of our UK oncology missions. Focusing specifically on early detection of lung cancer, our partnership with Clinithink is a great example within AstraZeneca Oncology of an external partnership with the common goal of improving UK cancer outcomes.” 
Dr. Satoshi Hori
Oncology Medical Affairs Head at AstraZeneca Oncology UK

Ready to talk?

Contact one of our specialists today.